Headlines

Biogen Inc. (BIIB) Q4 2025 (USD): adj. EPS 1.99 (exp. 1.62), Revenue 2.3bln (exp. 2.20bln)

Newsquawk Staff ·

GUIDANCE

  • FY EPS view 15.25-16.25 (exp. 15.01)

What it means

Biogen's Q4 2025 results beat expectations significantly on both earnings per share and revenue, which likely reflects strong operational performance and may boost investor sentiment. The upward revision in their FY EPS guidance also suggests confidence in sustained profitability moving forward, potentially impacting share price positively. This could have implications across the biotech sector, influencing peer performances and market valuations.

Related headlines